UBASH3A Regulates the Synthesis and Dynamics of TCR–CD3 Complexes

• Published in: The Journal of immunology (1950) Vol. 203; no. 11; pp. 2827 - 2836
• Main Authors: Ge, Yan, Paisie, Taylor K, Chen, Sixue, Concannon, Patrick
• Format: Journal Article
• Language: English
• Published: United States 01.12.2019
• Subjects: Adaptor Proteins, Signal Transducing - deficiency; Adaptor Proteins, Signal Transducing - immunology; CD3 Complex - immunology; Cells, Cultured; HEK293 Cells; Humans; Jurkat Cells; Receptors, Antigen, T-Cell - immunology
• ISSN: 0022-1767; 1550-6606; 1550-6606
• DOI: 10.4049/jimmunol.1801338

The TCR–CD3 complex is a multicomponent membrane receptor, the expression of which is tightly regulated in thymocytes, as well as in mature T cells both at steady state and upon stimulation. In this study, we report novel roles for UBASH3A in TCR–CD3 synthesis and turnover. UBASH3A is a negative regulator of T cell function and plays a broad role in autoimmunity. We show that modulation of UBASH3A levels in unstimulated Jurkat cells leads to altered amounts of total cellular CD3 chains and of cell-surface TCR–CD3 complexes; in contrast, UBASH3A does not affect the level of cell-surface CD28, an important T cell costimulatory receptor. Upon TCR engagement, UBASH3A enhances the downmodulation of cell-surface TCR–CD3. Mass spectrometry and protein–protein interaction studies uncover novel associations between UBASH3A and components of several cellular pathways involved in the regulation of TCR–CD3 turnover and dynamics, including endoplasmic reticulum–associated protein degradation, cell motility, endocytosis, and endocytic recycling of membrane receptors. Finally, we demonstrate that the SH3 domain of UBASH3A mediates its binding to CBL-B, an E3 ubiquitin ligase that negatively regulates CD28-mediated signaling and, hence, T cell activation. In summary, this study provides new mechanistic insights into how UBASH3A regulates T cell activation and contributes to autoimmunity. The interaction between UBASH3A and CBL-B may synergistically inhibit T cell function and affect risk for type 1 diabetes, as both genes have been shown to be associated with this autoimmune disease.